array:22 [ "pii" => "S1576988724000736" "issn" => "15769887" "doi" => "10.1016/j.vacun.2024.07.004" "estado" => "S200" "fechaPublicacion" => "2024-07-29" "aid" => "369" "copyright" => "Elsevier España, S.L.U.. All rights reserved" "copyrightAnyo" => "2024" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:17 [ "pii" => "S1576988724000700" "issn" => "15769887" "doi" => "10.1016/j.vacun.2024.07.001" "estado" => "S200" "fechaPublicacion" => "2024-07-30" "aid" => "366" "copyright" => "Elsevier España, S.L.U." "documento" => "article" "crossmark" => 0 "subdocumento" => "sco" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "es" => array:9 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "Erradicación del sarampión: todavía un largo y difícil camino" "tienePdf" => "es" "tieneTextoCompleto" => "es" "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Measles eradication: Still a long and winding road" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Fernando Moraga-Llop, Magda Campins-Martí" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Fernando" "apellidos" => "Moraga-Llop" ] 1 => array:2 [ "nombre" => "Magda" "apellidos" => "Campins-Martí" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1576988724000700?idApp=UINPBA00004N" "url" => "/15769887/unassign/S1576988724000700/v1_202407300435/es/main.assets" ] "itemAnterior" => array:17 [ "pii" => "S1576988724000487" "issn" => "15769887" "doi" => "10.1016/j.vacun.2024.06.004" "estado" => "S200" "fechaPublicacion" => "2024-07-15" "aid" => "361" "copyright" => "The Authors" "documento" => "article" "crossmark" => 0 "subdocumento" => "rev" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "es" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Revisión</span>" "titulo" => "Revisión de los formatos de presentación de vacunas y sus principales características" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Review of vaccine packaging formats and their key features" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "f0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 3292 "Ancho" => 2382 "Tamanyo" => 480919 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "al0005" "detalle" => "Figura " "rol" => "short" ] ] "descripcion" => array:1 [ "es" => "<p id="sp0005" class="elsevierStyleSimplePara elsevierViewall">Algoritmo de búsqueda realizada e inclusión de artículos, basado en el protocolo utilizado para publicación de revisiones panorámicas, PRISMA-ScR<a class="elsevierStyleCrossRef" href="#bb0035"><span class="elsevierStyleSup">7</span></a>.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Silvia Domínguez-Fernández, Jose Antonio Forcada-Segarra, Inmaculada Cuesta-Esteve, Silvia Fernández-Fernández, Rosario Cáceres Fernández-Bolaños, Guadalupe Fontán-Vinagre, Roberto Guerrero-Menéndez" "autores" => array:7 [ 0 => array:2 [ "nombre" => "Silvia" "apellidos" => "Domínguez-Fernández" ] 1 => array:2 [ "nombre" => "Jose Antonio" "apellidos" => "Forcada-Segarra" ] 2 => array:2 [ "nombre" => "Inmaculada" "apellidos" => "Cuesta-Esteve" ] 3 => array:2 [ "nombre" => "Silvia" "apellidos" => "Fernández-Fernández" ] 4 => array:2 [ "nombre" => "Rosario" "apellidos" => "Cáceres Fernández-Bolaños" ] 5 => array:2 [ "nombre" => "Guadalupe" "apellidos" => "Fontán-Vinagre" ] 6 => array:2 [ "nombre" => "Roberto" "apellidos" => "Guerrero-Menéndez" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1576988724000487?idApp=UINPBA00004N" "url" => "/15769887/unassign/S1576988724000487/v1_202407150420/es/main.assets" ] "en" => array:19 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Special Articles</span>" "titulo" => "Designing an immuno-epitope candidate vaccine from (Opa, ProA, ProB, RmpM and BamD) proteins against <span class="elsevierStyleItalic">Neisseria gonorrhoeae</span> and <span class="elsevierStyleItalic">Neisseria meningitides</span>" "tieneTextoCompleto" => true "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Ali Adel Dawood" "autores" => array:1 [ 0 => array:4 [ "nombre" => "Ali Adel" "apellidos" => "Dawood" "email" => array:1 [ 0 => "aad@uomosul.edu.iq" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cr0005" ] ] ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Dept. of Medical Biology, College of Medicine, University of Mosul, Mosul, Iraq" "identificador" => "af0005" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cr0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author<span class="elsevierStyleBold">.</span>" ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Diseño de una vacuna candidata a inmunoepítopo a partir de proteínas (Opa, ProA, ProB, RmpM y BamD) contra <span class="elsevierStyleItalic">Neisseria gonorrhoeae</span> y <span class="elsevierStyleItalic">Neisseria meningitidis</span>" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "f0035" "etiqueta" => "Fig 7" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr7.jpeg" "Alto" => 760 "Ancho" => 2049 "Tamanyo" => 142484 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "al0035" "detalle" => "Fig " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="sp0035" class="elsevierStyleSimplePara elsevierViewall">A: Antigen count and Antibody titers arbitrary scale. B: Concentration of cytokines and interleukins. D in the inset plot is danger signal.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="s0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0025">Introduction</span><p id="p0005" class="elsevierStylePara elsevierViewall">There is no denying that vaccinations against infectious illnesses have improved human health. Vaccine development against challenging bacterial illnesses, particularly those caused by drug-resistant microorganisms, is still critically needed. In recent years, a growing number of research have investigated gonorrhea vaccine candidates' ability to elicit immunological responses in laboratory animals. However, just a few studies have looked at its ability to activate defensive responses that may increase infection clearance and reduce sickness duration.<a class="elsevierStyleCrossRef" href="#bb0005"><span class="elsevierStyleSup">1</span></a></p><p id="p0010" class="elsevierStylePara elsevierViewall">The annual incidence of meningococcal disease is between 0.5 and 10 per 100 000. During epidemics, the number may rise to 400. The first successful immunizations against meningococcal illness were composed of pure polysaccharides against 4 disease-causing serotypes.<a class="elsevierStyleCrossRef" href="#bb0010"><span class="elsevierStyleSup">2</span></a> Recently, there is no approved vaccinations available for meningococcal serotype B (MenB) illness, which causes 32% of all meningococcal diseases. The vaccine's premise was polysaccharide for bacterial capsule, which is identical to the widely dispersed human polysaccharide such as N-acetyl neuraminic acid, which is an autoantigen and is thought to be immunologically weak in humans. Moreover, using this polysaccharide in a vaccination could induce autoantibodies.<a class="elsevierStyleCrossRef" href="#bb0015"><span class="elsevierStyleSup">3</span></a><span class="elsevierStyleSup">,</span><a class="elsevierStyleCrossRef" href="#bb0020"><span class="elsevierStyleSup">4</span></a></p><p id="p0015" class="elsevierStylePara elsevierViewall">Since 2009, when gonorrhea rates hit a historic low, there has been a simultaneous increase in antibiotic-resistant cases. The frequency of diseases increased by 111% between 2009 and 2020. In 2020, more than half of gonococcal isolates exhibited at least one kind of antibiotic resistance. This has led to concerns about increasing resistance.<a class="elsevierStyleCrossRef" href="#bb0025"><span class="elsevierStyleSup">5</span></a></p><p id="p0020" class="elsevierStylePara elsevierViewall">The benefits of a successful gonorrhea vaccine would include preventing infection, reducing the need for medications, and reducing the frequency of resistant strains. However, because the correlates of immunological protection against the infection are poorly known, the development of a gonorrhea vaccine has been difficult. Meningococcal B vaccines containing outer membrane have been shown to protect against gonorrhea related hospitalization, despite the fact that meningococci and gonococci share comparable OMVs.<a class="elsevierStyleCrossRef" href="#bb0030"><span class="elsevierStyleSup">6</span></a><span class="elsevierStyleSup">,</span><a class="elsevierStyleCrossRef" href="#bb0035"><span class="elsevierStyleSup">7</span></a> Although, <span class="elsevierStyleItalic">Neisseria gonorrhoeae</span> and <span class="elsevierStyleItalic">Neisseria meningitidis</span> share up to 85% of their genomes, and several of their antigens are genetically identical, gonococci express the Neisseria heparin-binding antigen 4CMenB, which contributes to cross-protection between the 2 species. Other OMV immunogenic proteins highly conserved in both Neisseria spp. may be possible targets for novel gonorrhea vaccines.<a class="elsevierStyleCrossRef" href="#bb0040"><span class="elsevierStyleSup">8</span></a><span class="elsevierStyleSup">,</span><a class="elsevierStyleCrossRef" href="#bb0045"><span class="elsevierStyleSup">9</span></a></p><p id="p0025" class="elsevierStylePara elsevierViewall">The current work sought to design and construct a vaccine that included <span class="elsevierStyleItalic">N. meningitidis</span> and <span class="elsevierStyleItalic">N. gonorrhoeae</span> species by identifying key proteins. The following proteins were chosen: <span class="elsevierStyleItalic">N. gonorrhoeae</span> produced the Opa protein, gamma-glutamyl phosphate reductase (ProA), and glutamate 5-kinase (ProB). The proteins selected for <span class="elsevierStyleItalic">N. meningitidis</span> are peptidoglycan-binding outer membrane protein (RmpM) and outer membrane protein assembly factor (BamD). The approaches were carried out using bioinformatics tools.</p></span><span id="s0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0030">Materials and methods</span><p id="p0030" class="elsevierStylePara elsevierViewall">The proteins data were obtained from the NCBI. The selected proteins from <span class="elsevierStyleItalic">N. gonorrhoeae</span> are Opa (STZ89234), ProA (GFL57776), and ProB (USJ71167), whereas RmpM (WP_263871268) and BamD (GFL57359) come from <span class="elsevierStyleItalic">N. meningitides.</span> The antigenicity, toxicity, and allergenicity of selected proteins were assessed using VaxiJen 2.0, ToxinPred, and AlgPred, respectively.</p><p id="p0035" class="elsevierStylePara elsevierViewall">The immunogenicity of CTL epitopes in protein sequences was determined using NetCTL 1.2. This prediction consists of 3 components. It starts by predicting the MHC-I binding peptide, then progresses to the C-terminal cleavage site and, finally, the vector transport efficiency program associated with antigen processing. The first 2 parameters are calculated via artificial neural networks. Furthermore, utilizing the IEDB server, HTL epitopes with high affinity for human alleles, such as HLA-DRB, were predicted. The percentage rate is inversely proportional to the epitope's binding affinity. The lower percentage rate indicates better correlation closeness. To increase the host's protective antibody response. The BCPred web server was then used to select B-cell epitopes and choose the best predicted epitopes.</p><p id="p0040" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">Neisseria</span> multi-epitope vaccine (NMEV) was created and tested by carefully combining the anticipated epitopes highlighted in the preceding rounds to create a peptide vaccine. CTL, HTL, and B-cell epitopes were connected using AAY, GPGPG, and KK links, respectively. Human β-defensin 3 was introduced at the start of the sequence. The sensitivity of the NMEV sequence was then assessed using the AlgPred server. The NMEV required to be antigenic in order to elicit the proper immunological response. The VaxiJen 2.0 server was used to anticipate NMEV antigenicity, using a default threshold of 0.4.</p><p id="p0045" class="elsevierStylePara elsevierViewall">ProtParam server was used to detect many physicochemical features of the NMEV, including its amino acid content, molecular weight, instability index, half-life, theoretical reactivity ratio, aliphatic index, and hydrophobicity. PSIPRED a free online program, was used to estimate the NMEV secondary structure. trRosetta tool was used to construct NMEV 3D structure. This software also employs the confidence parameter to evaluate the accuracy of constructed 3D structures. All models were assessed using the <span class="elsevierStyleItalic">p</span>-value and the distance test. The 3D structure was enhanced using BIOVIA. During this approach, the protein side chain was reconstructed and repackaged using CASP10 optimization, followed by relaxing using MD simulations. The quality model was analyzed using online technologies such as ERRAT2 on the PROCHCK server. NMEV's 3D structure was improved and displayed with PyMol software.</p><p id="p0050" class="elsevierStylePara elsevierViewall">Immune simulation helps anticipate the interaction between foreign proteins and the immune system. The C-ImSim server was utilized. This program is a part of a recent trend in promising models that investigate autonomous creatures in either virtual or real-world settings. The server measures the immune system's response to the antigen. When the vaccine is delivered, numerous immunological chemicals such as antibodies, interferons, and cytokines are anticipated to be produced. Furthermore, Th1 and Th2 responses are predicted by showing the Simpson index or diversity measure at their default settings.</p><p id="p0055" class="elsevierStylePara elsevierViewall">The NMEV was performed docking with TLR3 (1ZIW) using the HDOCK server to reveal the vaccine's interactions and binding orientation with TLR3. Docking was used to divide a molecule's surface into small yet precisely structured patches. These patches serve as a basic pattern and can be seen as a puzzle game. The matching algorithms choose the optimal mending patches to get the best outcomes. The global energy may be divided into 3 components: van der Waals interaction energy, atomic contact energy (attracting and repelling), and hydrogen bond energy.</p></span><span id="s0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0035">Results</span><p id="p0060" class="elsevierStylePara elsevierViewall">As shown in <a class="elsevierStyleCrossRef" href="#t0005">Table 1</a>, 31 peptides of 9 mer length were identified as potential CTL epitopes from the selected proteins. Additionally, at threshold 0.75, nomination based on strong binding affinity and antigenic character demonstrated effectiveness. As definitive CTL epitopes, 5 of them are regarded as such. The greatest total score was used to determine the final set of CTL epitopes.</p><elsevierMultimedia ident="t0005"></elsevierMultimedia><p id="p0065" class="elsevierStylePara elsevierViewall">When predicting HTL episodes, the 5 HLA-DRB1 variants reflect 5 different human alleles. Any peptide sequence with the highest binding affinity was considered. Because they have strong antigenic properties, epitopes with the lowest percentage rank and highest scores were chosen for inclusion in the final vaccine. Antigenic and high affinity HTL epitopes have been shown to bind to MHC alleles. The related 15-mer alleles are displayed, <a class="elsevierStyleCrossRef" href="#t0010">Table 2</a>.</p><elsevierMultimedia ident="t0010"></elsevierMultimedia><p id="p0070" class="elsevierStylePara elsevierViewall">B cell epitopes are a mediator of the humoral immune response, which results in the induction of long-term immunity. Since a B-cell epitope's likelihood increases with its score, the ones with the highest scores were selected. The vaccine has 16 mer epitopes with scores better than 0.9. <a class="elsevierStyleCrossRef" href="#t0015">Table 3</a> shows the 5 epitopes with the highest scores among the 5 proteins being investigated.</p><elsevierMultimedia ident="t0015"></elsevierMultimedia><p id="p0075" class="elsevierStylePara elsevierViewall">Five of each CTL, HTL, and B-cell loop were joined with one another using various linkers to create the final NMEV map. AAY, GPGPG, and KK were the respective linkers. Moreover, this sequence is complemented by the first component (Human β-defensin 3) to conserve the vaccine. A total of 297 amino acids made up the NMEV sequence. <a class="elsevierStyleCrossRef" href="#f0005">Fig. 1</a> shows a schematic illustration of the final batch vaccine's structure.</p><elsevierMultimedia ident="f0005"></elsevierMultimedia><p id="p0080" class="elsevierStylePara elsevierViewall">The PSIPRED and PROCHECK tools were used to generate the 2D structure of the NMEV. These tools were utilized to assess the sequence's features, physiochemical, and residue properties. <a class="elsevierStyleCrossRef" href="#f0010">Fig. 2</a> shows the physiochemical and stereochemical features of the divide sequence. The charts are defined by 7 distinct parameter options. The absolute variation from the mean Chi-1 value is less than 15% of the overall deviation of residues. The absolute deviation from the mean of omega torsion indicates 5 key spots in the sequence that are significantly deviated, as represented by the color red. The departure of zeta torsion shows 3 residues from other locations in red. Depending on the location of each epitope sequence, the percentage of residues in the main chain execute distinct alpha helix, beta strand, and random coil functions. The option controls which residues are labeled on the Ramachandran plot, hence option 0 only identifies residues in prohibited zones. Option 1 detects waste in both limited and generous locations. This may be seen in the distribution of residues with other parameters or in the Ramachandran plot system, where they are scattered throughout the plot, as seen in <a class="elsevierStyleCrossRef" href="#f0015">Fig. 3</a>. Based on an investigation of 118 structures with a resolution of at least 2.0 A° and an R-factor of no more than 20%, a good quality model for the proposed vaccination has more than 90% in the most favorable areas.</p><elsevierMultimedia ident="f0010"></elsevierMultimedia><elsevierMultimedia ident="f0015"></elsevierMultimedia><p id="p0085" class="elsevierStylePara elsevierViewall">The G-factor measures how normal or unusual a stereochemical property is. The application creates a PDB output file and replaces the atoms' temperature factors with values representing the G-factors of the necessary torsion angles. The red sections of the structure represent unusual torsion angles, which correlate to negative G-factors, which were scarce in the overall planned inoculum. Colors are scaled in accordance with the maximum and least B-values observed inside the tailings site, therefore there will always be red patches corresponding to the maximum B-values, regardless of how large or small the absolute B-values.</p><p id="p0090" class="elsevierStylePara elsevierViewall">It is evident by analyzing the secondary composition of the vaccine suggested by ERRAT2 that the quality factor of the model is 79.787. The remaining residues, which make up a tiny portion and are indicated in red in <a class="elsevierStyleCrossRef" href="#f0020">Fig. 4</a>, lie outside the designated region, which is what sets this categorization apart. On the error axis, 2 lines show the degree of confidence with which areas exceeding that error value may be dismissed. It is defined as the percentage of epitope sequences with estimated error values less than the 95% rejection level. The majority of the residues are highlighted in the first region below the 2 lines, which is commonly used to construct fine, high-resolution structures. The average overall quality factor for lower resolutions (2.5–3 A°) is around 91%.</p><elsevierMultimedia ident="f0020"></elsevierMultimedia><p id="p0095" class="elsevierStylePara elsevierViewall">The distributions in the epitope sequence are transformed into real-valued maps by the trRosetta script, which subsequently displays the maps using the Python 2 distribution. When creating the secondary structure, different angles are employed to identify deviations from the center principal axis and the degree to which the residues resemble this distribution. It can be seen from <a class="elsevierStyleCrossRef" href="#f0025">Fig. 5</a> that the residual distribution is almost central, with only a slight angle torsion between the angles, and that the degrees of distribution of these residuals over the whole sequence are dependent on many angles. Subsequently, the software incorporates these axes at their angles to create a 3D structure in a number of suggested, categorized, and anticipated models, including 5 NMEV models, <a class="elsevierStyleCrossRef" href="#f0030">Fig. 6</a>.</p><elsevierMultimedia ident="f0025"></elsevierMultimedia><elsevierMultimedia ident="f0030"></elsevierMultimedia><p id="p0100" class="elsevierStylePara elsevierViewall">One of the principles of vaccine design is to assess it immunologically before testing it in the lab to ensure that the targeted epitopes stimulate immune system cells. <a class="elsevierStyleCrossRef" href="#f0035">Fig. 7</a>A displays a large amount of antigen throughout the first 5 days after the vaccination was administered experimentally, followed by a decrease in quantity at the conclusion of the fifth day. The immune system responds at the end of the fourth day by producing IgM and (IgG<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>IgM) together. It peaks on the 15th day following the injection and then starts to decline quickly. In contrast to the other kinds, (IgG1<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>IgG2) begins to develop on the sixth day, and the curve stabilizes after the 15th day. On the other hand, IgG2 levels stay steady, with no rise in the curve. The production of interleukins and cytokines is crucial for the immune response. The current investigation revealed that IFN-G production was substantially higher than the other types of cytokines that emerged in the blood from the first day of injection, and then decreased suddenly in an unexpected manner after the twentieth day of injection (<a class="elsevierStyleCrossRef" href="#f0035">Fig. 7</a>B).</p><elsevierMultimedia ident="f0035"></elsevierMultimedia><p id="p0105" class="elsevierStylePara elsevierViewall">The immunological response causes an increase in the number of T-helper cells of both kinds beginning within hours of vaccination administration. The number of cells begins to expand dramatically after the fourth day after injection and remains stable until the 10th day. After the 30th day of injection, the number curve begins to fall, <a class="elsevierStyleCrossRef" href="#f0040">Fig. 8</a>A, B and C. The number of cytotoxic T-cell appears to fluctuate when compared to non-memory cells that have memory along the route of the curve, <a class="elsevierStyleCrossRef" href="#f0040">Fig. 8</a>D and E). The number of natural killer cells begins to climb or fall following the predicted curve until the number declines dramatically after the thirtieth day of injection, as seen in <a class="elsevierStyleCrossRef" href="#f0040">Fig. 8</a>F.</p><elsevierMultimedia ident="f0040"></elsevierMultimedia><p id="p0110" class="elsevierStylePara elsevierViewall">Predicting the binding complexes between 2 proteins is done by the HDOCK using global docking. As such, the docking task does not require any information regarding the binding point. In order to increase the accuracy of the projected models, the server allows to specify the binding site residues, should such information be available. Anchoring scores are obtained using the knowledge-based iterative functions of ITScorePP and ITScorePR. The lower docking score suggests a more plausible binding model, but the result should not be construed as an indication of true binding between 2 proteins because it has not been calibrated against experimental data. The docking program generates 100 models for protein binding, but the top 10 docking models between the proposed NMEV and TLR3 are chosen based on the docking score and confidence score, as shown in <a class="elsevierStyleCrossRef" href="#f0045">Fig. 9</a>. Legand RMSD, docking score and confidence score are illustrated in <a class="elsevierStyleCrossRef" href="#t0020">Table 4</a>.</p><elsevierMultimedia ident="f0045"></elsevierMultimedia><elsevierMultimedia ident="t0020"></elsevierMultimedia><p id="p0115" class="elsevierStylePara elsevierViewall">The NMEV amino acid sequence was translated to DNA utilizing the Reverse Translate service. 297 amino acids were converted to 891 bps. SnapGene was used to generate the whole NMEV DNA sequence, including primers and restriction enzymes, as seen in <a class="elsevierStyleCrossRef" href="#f0050">Fig. 10</a>. SfcI or PstI were chosen as forward restriction enzymes, while PuvI was used as a reverse restriction enzyme.</p><elsevierMultimedia ident="f0050"></elsevierMultimedia><p id="p0120" class="elsevierStylePara elsevierViewall">According to the PortParam analysis, the negative charge residues were 25 and the positive charge residues were 48. The half-life of <span class="elsevierStyleItalic">E. coli</span> is 10 h. The aliphatic index is 73.64, and the average hydropathicity is -0.502. The designed primers were determined using the AMUSER program, with the forward sequence 34 mer (ACCGCGGCAUTATTAACACCCTGCAGAAATATTA) at 52.8°C and the reverse primer sequence 29 mer (ATGCCGCGGUTCGCTTTCGGATCGCGAT) at 59.1°C. The primers have a GC content of 55.56%.</p></span><span id="s0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0040">Discussion</span><p id="p0125" class="elsevierStylePara elsevierViewall">Vaccination is the only effective strategy to reduce disease prevalence and attenuate long-term consequences. Six of the 12 meningococcal serogroups indicate illness states. Four capsular polysaccharide vaccines have been authorized against them: A, C, W, and Y3. However, as an alternative technique, meningococcal outer membrane vesicles have been used to manufacture various immunizations that have successfully cured CL.<a class="elsevierStyleCrossRefs" href="#bb0050"><span class="elsevierStyleSup">10–12</span></a></p><p id="p0130" class="elsevierStylePara elsevierViewall">The current research employs computational modeling methodologies to create NMEV. A typical pipeline was used to carry out the multistep systematic approach, which began with predicting antigenic and allergenic features. The second phase involved predicting and shortlisting CTL, HTL, and B cell epitopes based on their combined score and percentile rank. Following antigenic, toxicological, and allergen evaluations, a multi-epitope vaccination was developed based on the identified ligand-binding epitopes. The physicochemical and stereochemical characteristics of the vaccine were investigated.</p><p id="p0135" class="elsevierStylePara elsevierViewall">The presence of visible antigenic epitopes on the surface is essential for efficient control and eradication of any bacterial disease. This is the primary goal for promoting effective immunizations. The developed vaccines are beneficial because, unlike standard immunizations, they are viable, exceedingly safe, non-toxic, pose minimal problems in immunocompromised people, and are simple to make. Therapeutic vaccines based on one or more proteins are very specific and immunogenic. Moreover, these vaccines can elicit both cellular and humoral protection. Constructed epitope vaccines have been developed to treat a variety of illnesses, including cholera, leishmaniasis, cancer, and some viruses.<a class="elsevierStyleCrossRef" href="#bb0065"><span class="elsevierStyleSup">13</span></a><span class="elsevierStyleSup">,</span><a class="elsevierStyleCrossRef" href="#bb0070"><span class="elsevierStyleSup">14</span></a></p><p id="p0140" class="elsevierStylePara elsevierViewall">Immunization is thought to be the most effective and safest process of avoiding infectious illnesses. Because proteomics data is easily accessible, the application of modern technology in developing epitope-based vaccinations raises the possibility of discovering novel antigenic sites using immunoinformatics approaches.<a class="elsevierStyleCrossRef" href="#bb0075"><span class="elsevierStyleSup">15</span></a><span class="elsevierStyleSup">,</span><a class="elsevierStyleCrossRef" href="#bb0080"><span class="elsevierStyleSup">16</span></a></p><p id="p0145" class="elsevierStylePara elsevierViewall">The development of a conventional vaccine against gonococci has been problematic due to the absence of specific correlates of immune protection and the presence of ambiguous protective immunity mechanisms. However, the drop in gonorrhea infections might be ascribed to the advent of vaccines based on <span class="elsevierStyleItalic">N. meningitidis</span>' outer membrane.<a class="elsevierStyleCrossRef" href="#bb0085"><span class="elsevierStyleSup">17</span></a><span class="elsevierStyleSup">,</span><a class="elsevierStyleCrossRef" href="#bb0090"><span class="elsevierStyleSup">18</span></a> Although there is growing evidence of the membrane vaccine's efficacy in numerous studies, ranging from 30% to 40%, the observational nature of these studies prevents proof of a causal influence. Long-term protection requires more investigation, since some studies indicate that protection against gonorrhea may decline after 3–4 years. Modeling studies indicate that even a vaccination with a 20% effectiveness probability can significantly reduce disease incidence. Women are more vulnerable to problems from gonococcal infections, thus any reduction in the prevalence of infections will benefit women's health internationally.<a class="elsevierStyleCrossRefs" href="#bb0095"><span class="elsevierStyleSup">19–21</span></a></p><p id="p0150" class="elsevierStylePara elsevierViewall">The paucity of recognized correlates of protective immunity poses a challenge for core antigen nominations and novel methods to gonococcal vaccine development. Previous research has shown that PorB is important in modifying the response to immunological stress, implying that efficient immunization against gonococci may emerge. Furthermore, the development of reduced levels of RmpM and a higher antibody response is linked to greater vulnerability to infection. In vitro investigations have revealed that IgG antibodies to RmpM may inhibit the production of other potentially protective antibodies against these infections. Additionally, serum antibody responses to lipopolysaccharides may provide some protection against re-infection.<a class="elsevierStyleCrossRefs" href="#bb0110"><span class="elsevierStyleSup">22–25</span></a></p><p id="p0155" class="elsevierStylePara elsevierViewall">This study evaluated 5 proteins, 3 of which were membranes and 2 of which were non-structural. The investigation found that the protein has antigenic characteristics and is the best candidate for vaccine creation. Our research identified 31 CTL epitopes, 37 HTL epitopes, and 31 B-cell epitopes as the most likely antigenic peptides. Five epitopes from each type of epitope were chosen to create the final vaccination that was considered. The vaccine's final formulation employed adjuvants and linkers to attach these epitopes to the final product. The vaccine has 297 amino acids. The NMEV vaccine candidate is described as a highly antigenic, non-allergenic, and non-toxic.</p><p id="p0160" class="elsevierStylePara elsevierViewall">Furthermore, the physicochemical and stereochemical properties of the proposed vaccine were determined to be acceptable. The interaction with TLR3 and its expression in the <span class="elsevierStyleItalic">E. coli</span> host were verified, allowing for further modification. Changes in the protein sequence are unlikely to affect the effectiveness of the vaccine against the two Neisseria species.</p><p id="p0165" class="elsevierStylePara elsevierViewall">Immune simulation revealed that the NMEV candidate induced a successful immune response, resulting in high titers of host immune components. Thus, our findings suggest that NMEV could be investigated in clinical trials in the future. The vaccine's safety, efficacy, and other attributes make it an attractive option for in vitro and in vivo testing.</p><p id="p0170" class="elsevierStylePara elsevierViewall">The NMEV vaccine candidate successfully elicited an immune response by predicting it using a computer algorithm. We recommend that clinical studies be conducted on potential NMEVs, both in vitro and in vivo, to determine their ability to stimulate immune responses against <span class="elsevierStyleItalic">N. gonorrhoeae</span> and <span class="elsevierStyleItalic">N. Meningismus</span>. The use of contemporary in silico methods for vaccine design is an important methodology in promoting the manufacture of an effective vaccine with minimal testing.<a class="elsevierStyleCrossRef" href="#bb0130"><span class="elsevierStyleSup">26</span></a></p></span><span id="s0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0045">Conclusions</span><p id="p0175" class="elsevierStylePara elsevierViewall">This work provides comprehensive knowledge of the structural basis for the development of vaccination against <span class="elsevierStyleItalic">N. gonorrhoeae</span> and <span class="elsevierStyleItalic">N. meningitis</span>. The proposed NMEV vaccine has the potential to elicit a strong immune response, requiring further research and in vivo testing against Neisseria infection.</p></span><span id="s0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0050">Funding</span><p id="p0180" class="elsevierStylePara elsevierViewall">This work was done with self-supporting.</p></span><span id="s0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0055">Author contributions</span><p id="p0185" class="elsevierStylePara elsevierViewall">Designing the idea, choosing programs, writing the manuscript, using software, writing the results, analyze and clarifying the purpose of the study were done by the corresponding author.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:13 [ 0 => array:3 [ "identificador" => "xres2211432" "titulo" => "Abstract" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "as0005" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec1854770" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres2211431" "titulo" => "Resumen" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "as0010" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec1854771" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "s0005" "titulo" => "Introduction" ] 5 => array:2 [ "identificador" => "s0010" "titulo" => "Materials and methods" ] 6 => array:2 [ "identificador" => "s0015" "titulo" => "Results" ] 7 => array:2 [ "identificador" => "s0020" "titulo" => "Discussion" ] 8 => array:2 [ "identificador" => "s0025" "titulo" => "Conclusions" ] 9 => array:2 [ "identificador" => "s0030" "titulo" => "Funding" ] 10 => array:2 [ "identificador" => "s0035" "titulo" => "Author contributions" ] 11 => array:2 [ "identificador" => "xack762380" "titulo" => "Acknowledgments" ] 12 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2024-05-22" "fechaAceptado" => "2024-07-08" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec1854770" "palabras" => array:5 [ 0 => "Docking" 1 => "Epitope" 2 => "Neisseria" 3 => "ProA" 4 => "Vaccine" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec1854771" "palabras" => array:5 [ 0 => "Docking" 1 => "Epítopo" 2 => "Neisseria" 3 => "ProA" 4 => "Vacuna" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<span id="as0005" class="elsevierStyleSection elsevierViewall"><p id="sp0075" class="elsevierStyleSimplePara elsevierViewall">The development of a conventional vaccine against gonococci has been difficult since there are no precise correlates of immune protection and the mechanisms of protective immunity are not yet understood. However, the drop in gonorrhea infections might be attributed to the development of vaccines based on <span class="elsevierStyleItalic">Neisseria meningitidis</span>' outer membrane. The goal of this research was to develop a multi-epitope vaccination utilizing proteins from <span class="elsevierStyleItalic">N. meningitidis</span> and <span class="elsevierStyleItalic">Neisseria gonorrhoeae</span>. A <span class="elsevierStyleItalic">Neisseria</span> Multi-Epitope Vaccine (NMEV), containing Opa, ProA, ProB, RmpM, and BamD, was developed using immunophysicochemical informatics techniques. The vaccine consists of 297 amino acids. Antigenicity and sensitivity to NMEV were evaluated. NMEV generates a substantial amount of immune cells and cytokines. The total quality factor of the NMEV 2D structure is around 91%. The vaccine's safety, effectiveness, and other properties make it an attractive option for in vitro and in vivo testing. The suggested NMEV subunit vaccine has the potential to elicit a strong immune response, necessitating additional in vitro and in vivo studies to eliminate Neisseria infections.</p></span>" ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "<span id="as0010" class="elsevierStyleSection elsevierViewall"><p id="sp0080" class="elsevierStyleSimplePara elsevierViewall">El desarrollo de una vacuna convencional contra los gonococos ha sido difícil porque no existen correlatos precisos de la protección inmunitaria y aún no se comprenden los mecanismos de la inmunidad protectora. Sin embargo, la disminución de las infecciones por gonorrea podría atribuirse al desarrollo de vacunas basadas en la membrana externa de Neisseria meningitidis. El objetivo de esta investigación fue desarrollar una vacuna multiepítopo utilizando proteínas de N. meningitidis y N. gonorrhoeae. Se desarrolló una vacuna multiepítopo contra Neisseria (NMEV), que contiene Opa, ProA, ProB, RmpM y BamD, utilizando técnicas informáticas inmunofisicoquímicas. La vacuna consta de 297 aminoácidos. Se evaluaron la antigenicidad y la sensibilidad al NMEV. NMEV genera una cantidad sustancial de células inmunes y citocinas. El factor de calidad total de la estructura NMEV 2D ronda el 91%. La seguridad, eficacia y otras propiedades de la vacuna la convierten en una opción atractiva para pruebas in vitro e in vivo. La vacuna de subunidad NMEV sugerida tiene el potencial de provocar una fuerte respuesta inmune, lo que requiere estudios adicionales in vitro e in vivo para eliminar las infecciones por Neisseria.</p></span>" ] ] "multimedia" => array:14 [ 0 => array:8 [ "identificador" => "f0005" "etiqueta" => "Fig 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 900 "Ancho" => 1895 "Tamanyo" => 234915 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "al0005" "detalle" => "Fig " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="sp0005" class="elsevierStyleSimplePara elsevierViewall">The 3D structure and the full sequence of constructed NMEV including: human β-defensin 3 (hBD3); (CTL, HTL, and B-cell epitopes); and (EAAAK, AAY, GPGPG, and KK linkers).</p>" ] ] 1 => array:8 [ "identificador" => "f0010" "etiqueta" => "Fig 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 990 "Ancho" => 2050 "Tamanyo" => 424219 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "al0010" "detalle" => "Fig " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="sp0010" class="elsevierStyleSimplePara elsevierViewall">Physiochemical and stereochemical analysis of the NMEV 2D structure.</p>" ] ] 2 => array:8 [ "identificador" => "f0015" "etiqueta" => "Fig 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 983 "Ancho" => 2049 "Tamanyo" => 165722 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "al0015" "detalle" => "Fig " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="sp0015" class="elsevierStyleSimplePara elsevierViewall">Ramachandran plot of NMEV with over 90% in the most favored regions.</p>" ] ] 3 => array:8 [ "identificador" => "f0020" "etiqueta" => "Fig 4" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr4.jpeg" "Alto" => 462 "Ancho" => 2052 "Tamanyo" => 95589 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "al0020" "detalle" => "Fig " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="sp0020" class="elsevierStyleSimplePara elsevierViewall">2D structure sequence analysis of NMEV using ERRAT2.</p>" ] ] 4 => array:8 [ "identificador" => "f0025" "etiqueta" => "Fig 5" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr5.jpeg" "Alto" => 1280 "Ancho" => 2049 "Tamanyo" => 239965 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "al0025" "detalle" => "Fig " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="sp0025" class="elsevierStyleSimplePara elsevierViewall">Predicted inter-residue distance and orientations of the NMEV full sequence.</p>" ] ] 5 => array:8 [ "identificador" => "f0030" "etiqueta" => "Fig 6" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr6.jpeg" "Alto" => 601 "Ancho" => 2049 "Tamanyo" => 130498 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "al0030" "detalle" => "Fig " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="sp0030" class="elsevierStyleSimplePara elsevierViewall">5 models for the 3D structure of anticipated NMEV.</p>" ] ] 6 => array:8 [ "identificador" => "f0035" "etiqueta" => "Fig 7" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr7.jpeg" "Alto" => 760 "Ancho" => 2049 "Tamanyo" => 142484 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "al0035" "detalle" => "Fig " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="sp0035" class="elsevierStyleSimplePara elsevierViewall">A: Antigen count and Antibody titers arbitrary scale. B: Concentration of cytokines and interleukins. D in the inset plot is danger signal.</p>" ] ] 7 => array:8 [ "identificador" => "f0040" "etiqueta" => "Fig 8" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr8.jpeg" "Alto" => 1031 "Ancho" => 2048 "Tamanyo" => 190224 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "al0040" "detalle" => "Fig " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="sp0040" class="elsevierStyleSimplePara elsevierViewall">A: TH-cell count (total and memory). B: TH-cell count divided/entity-state (acctive, resting, anergic and duplicating). C: TH-cell count all types/state. D: TC count (total and memory). E: TC count/entity state. F: Total count of NK cell.</p>" ] ] 8 => array:8 [ "identificador" => "f0045" "etiqueta" => "Fig 9" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr9.jpeg" "Alto" => 930 "Ancho" => 2049 "Tamanyo" => 387985 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "al0045" "detalle" => "Fig " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="sp0045" class="elsevierStyleSimplePara elsevierViewall">Predicated 10 models of molecular docking between NMEV (rainbow color) and TLR3 receptor (green color).</p>" ] ] 9 => array:8 [ "identificador" => "f0050" "etiqueta" => "Fig 10" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr10.jpeg" "Alto" => 1109 "Ancho" => 1305 "Tamanyo" => 166732 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "al0050" "detalle" => "Fig 1" "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="sp0050" class="elsevierStyleSimplePara elsevierViewall">The NMEV DNA sequence reveals primer locations as well as many restriction enzyme possibilities.</p>" ] ] 10 => array:8 [ "identificador" => "t0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "al0055" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Protein \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">CTL epitopes at threshold 0.75 \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Opa \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">AYEHITHDY, RIALDYARY, HTDKGTFKA, GTFKAESNY, DTGTRFKPY, LTLDTGYRY \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">ProA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">AMGVIGIIY, TSDAAALAL, RLDPQAARY, GADDFDTEF, DFDTEFLDY, AADYFTTHI, \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">FTDGGEFGL, LKELTSYKY \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">ProB \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">GQGLLMEEY, LLTDIDGLY, LTDIDGLYT, AAESGVPVY, RTQKQWLAF, \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">TQKQWLAFY, YSESRGGVY \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">RmpM \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">LSALFVALL, YGECWKNAY, RTEAQDNLK, HTDFMGSDK, GSDKYNQAL \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">BamD \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">RQSQLDTAY, SQLDTAYAY, QLDTAYAYY, SLAILELAY, PDDMPWWRY \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab3607569.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="sp0055" class="elsevierStyleSimplePara elsevierViewall">Predicted CTL epitopes with 9 mer.</p>" ] ] 11 => array:8 [ "identificador" => "t0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "al0060" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Protein \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Allele \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Epitope sequence \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Score \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HLA-DRB1*15:01 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">GTRFKPYVGARVGLG \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.85 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HLA-DRB1*15:01 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">TGTRFKPYVGARVGL \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.8164 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HLA-DRB1*15:01 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">DTGTRFKPYVGARVG \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.7896 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Opa \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HLA-DRB1*15:01 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">EDQVTVTINHIVEGP \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.7387 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HLA-DRB1*15:01 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">TRFKPYVGARVGLGK \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.7351 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HLA-DRB1*15:01 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">GVGIDITPNLTLDTG \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.6583 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HLA-DRB1*15:01 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">VEDQVTVTINHIVEG \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.6368 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HLA-DRB1*15:01 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">AGVGIDITPNLTLDT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.5357 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HLA-DRB1*15:12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">GLLMEEYTANLSSDG \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.6994 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HLA-DRB1*15:13 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">KQWLAFYSESRGGVY \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.6524 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HLA-DRB1*15:14 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">GHELVLVSSGAVAAG \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.6539 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">ProB \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HLA-DRB1*15:15 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">QKQWLAFYSESRGGV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.6293 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HLA-DRB1*15:16 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">QGLLMEEYTANLSSD \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.5887 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HLA-DRB1*15:17 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">TQKQWLAFYSESRGG \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.5118 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HLA-DRB1*15:18 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">AGHELVLVSSGAVAA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.5223 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HLA-DRB1*15:19 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">GGMLTKIKAATIAAE \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.4173 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HLA-DRB1*15:21 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">TGIVHIYIDKDADWD \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.8994 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HLA-DRB1*15:22 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">GTGIVHIYIDKDADW \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.8513 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HLA-DRB1*15:23 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">DKALRIVYNAKTGRP \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.825 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">ProA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HLA-DRB1*15:24 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">TGTGIVHIYIDKDAD \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.8066 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HLA-DRB1*15:25 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">GIVHIYIDKDADWDK \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.7605 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HLA-DRB1*15:26 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">WDKALRIVYNAKTGR \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.7531 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HLA-DRB1*15:27 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">AGLIRAVVENAVVPV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.6242 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HLA-DRB1*15:38 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">DVKIRSIVTRQVVPA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.816 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HLA-DRB1*15:39 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">VDVKIRSIVTRQVVP \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.7583 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HLA-DRB1*15:40 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">VKIRSIVTRQVVPAH \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.5713 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">RmpM \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HLA-DRB1*15:41 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">RVDVKIRSIVTRQVV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.5446 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HLA-DRB1*15:42 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">EASVQGYTVSGQSNE \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.3869 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HLA-DRB1*15:43 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">IVTRQVVPAHNHHQH \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.3642 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HLA-DRB1*15:44 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SVRVEGHTDFMGSDK \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.3181 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HLA-DRB1*15:46 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">KKIIGSYQNTRYVEE \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.9011 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HLA-DRB1*15:47 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">AKKIIGSYQNTRYVE \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.8592 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HLA-DRB1*15:48 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">AELVQRFPNSKYAAD \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.7522 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">BamD \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HLA-DRB1*15:49 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">RAKKIIGSYQNTRYV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.7245 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HLA-DRB1*15:50 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">KIIGSYQNTRYVEES \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.7079 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HLA-DRB1*15:51 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">FAELVQRFPNSKYAA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.6483 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HLA-DRB1*15:52 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">ELVQRFPNSKYAADA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.5247 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab3607568.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="sp0060" class="elsevierStyleSimplePara elsevierViewall">Predicted HTL epitopes with 15 mer.</p>" ] ] 12 => array:8 [ "identificador" => "t0015" "etiqueta" => "Table 3" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "al0065" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Protein \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Epitope sequence \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Start position \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Score \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">YNTWRHGKHIHAEQTK \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">53 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.91 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">TVTINHIVEGPKNAHD \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">133 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.91 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowgroup " rowspan="2" align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Opa</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">MNYAYEHITHDYPADN \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.91 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">VAGVGIDITPNLTLDT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">164 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.89 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">ETDHTDKGTFKAESNY \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">80 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.88 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">FGNWRIALDYARYNTW \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">41 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.87 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">QSRSIRRVGFGAVAGV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">152 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.86 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">LTDIDGLYTGNPNSNP \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">167 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.92 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HFSRMDTVTVYSKATK \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">306 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.9 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowgroup " rowspan="2" align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">ProB</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">PVYICSSLKPDSLAEA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">229 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.9 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">AGGSGSANGTGGMLTK \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">201 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.89 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">DDWISITPEIRLLLTE \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">353 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.88 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">LKSRKAKGVFIHRDDW \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">340 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.87 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">MGVIGIIYESRPNVTS \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">104 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.97 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowgroup " rowspan="2" align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">ProA</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">TGTGIVHIYIDKDADW \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">212 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.93 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">VGHIEARGTHHSDGIV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">324 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.92 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">RGRIEAGLPPVRFRLD \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">271 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.92 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">GGEAAGADDFDTEFLD \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">294 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.9 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">LSERRAYVVANNLVSN \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">153 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.91 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">TISLSAKTLFGFDKDS \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">96 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.88 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowgroup " rowspan="2" align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">RmpM</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">CGDAVAAPEPEPEPEP \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">63 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.87 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SGTAVAGEASVQGYTV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">17 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.87 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">KASQGRVECGDAVAAP \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">55 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.84 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">ACIEPDRRVDVKIRSI \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">213 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.83 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NEMSVARYYMKRGAYI \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">180 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.91 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">KLASQDWSDRDPKANR \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">129 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.9 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">BamD \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">ILESRFPTSRHARQSQ \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">60 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.87 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">LDTAYAYYKDDEKDKA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">76 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.86 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">DKPQLAADTRRVLETN \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">229 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.86 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">YMKRGAYIAAANRAKK \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">188 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.85 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab3607567.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="sp0065" class="elsevierStyleSimplePara elsevierViewall">Predicted linear B-cell epitopes with 16 mer.</p>" ] ] 13 => array:8 [ "identificador" => "t0020" "etiqueta" => "Table 4" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "al0070" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Rank \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">M 1 \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">M 2 \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">M 3 \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">M 4 \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">M 5 \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">M 6 \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">M 7 \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">M 8 \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">M 9 \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">M 10 \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Docking score \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">−343 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">−339.6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">−336.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">−334.4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">−334.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">−332.1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">−329.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">−328.0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">−327.8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">−326.0 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Confidence \t\t\t\t\t\t\n \t\t\t\t</td><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowgroup " rowspan="2" align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.9794</td><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowgroup " rowspan="2" align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.978</td><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowgroup " rowspan="2" align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.9765</td><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowgroup " rowspan="2" align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.9756</td><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowgroup " rowspan="2" align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.9756</td><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowgroup " rowspan="2" align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.9745</td><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowgroup " rowspan="2" align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.9731</td><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowgroup " rowspan="2" align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.9724</td><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowgroup " rowspan="2" align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.9723</td><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowgroup " rowspan="2" align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.9713</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Score \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Ligand rmsd (Å) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">95.95 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">88.17 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">84.26 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">80.84 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">78.12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">76.13 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">88.56 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">78.38 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">80.49 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">79.43 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab3607570.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="sp0070" class="elsevierStyleSimplePara elsevierViewall">Docking analysis score presents docking score, confidence score and ligand RMSD for 10 models</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bs0005" "bibliografiaReferencia" => array:26 [ 0 => array:3 [ "identificador" => "bb0005" "etiqueta" => "1." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A novel gonorrhea vaccine composed of MetQ lipoprotein formulated with CpG shortens experimental murine infection" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A.E. Sikora" 1 => "C. Gomez" 2 => "A. Le Van" 3 => "B.I. Baarda" 4 => "S. Darnell" 5 => "F.G. Martinez" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.vaccine.2020.10.077" "Revista" => array:7 [ "tituloSerie" => "Vaccine" "fecha" => "2020" "volumen" => "38" "numero" => "51" "paginaInicial" => "8175" "paginaFinal" => "8184" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33162204" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bb0010" "etiqueta" => "2." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "NadA, a novel vaccine candidate of <span class="elsevierStyleItalic">Neisseria meningitidis</span>" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Comanducci" 1 => "S. Bambini" 2 => "B. Brunelli" 3 => "J. Adu-Bobie" 4 => "B. Aricò" 5 => "B. Capecchi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1084/jem.20020407" "Revista" => array:7 [ "tituloSerie" => "J Exp Med." "fecha" => "2002" "volumen" => "195" "numero" => "11" "paginaInicial" => "1445" "paginaFinal" => "1454" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12045242" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bb0015" "etiqueta" => "3." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Meningococcal disease in Europe: epidemiology, mortality, and prevention with conjugate vaccines" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "K. Cartwright" 1 => "N. Noah" 2 => "H. Peltola" 3 => "Meningococcal Disease Advisory Board" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/s0264-410x(01)00205-5" "Revista" => array:7 [ "tituloSerie" => "Vaccine" "fecha" => "2001" "volumen" => "19" "numero" => "31" "paginaInicial" => "4347" "paginaFinal" => "4356" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11534497" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bb0020" "etiqueta" => "4." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Antibodies to polysialic acid and its N-propyl derivative: binding properties and interaction with human embryonal brain glycopeptides" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Häyrinen" 1 => "H. Jennings" 2 => "H.V. Raff" 3 => "G. Rougon" 4 => "N. Hanai" 5 => "R. Gerardy-Schahn" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/infdis/171.6.1481" "Revista" => array:6 [ "tituloSerie" => "J Infect Dis." "fecha" => "1995" "volumen" => "171" "numero" => "6" "paginaInicial" => "1481" "paginaFinal" => "1490" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bb0025" "etiqueta" => "5." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prevention of <span class="elsevierStyleItalic">Neisseria gonorrhoeae</span> with meningococcal B vaccine: a matched cohort study in Southern California" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K.J. Bruxvoort" 1 => "J.A. Lewnard" 2 => "L.H. Chen" 3 => "H.F. Tseng" 4 => "J. Chang" 5 => "J. Veltman" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/cid/ciac436" "Revista" => array:7 [ "tituloSerie" => "Clin Infect Dis." "fecha" => "2023" "volumen" => "76" "numero" => "3" "paginaInicial" => "e1341" "paginaFinal" => "e1349" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35642527" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bb0030" "etiqueta" => "6." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effectiveness of a group B outer membrane vesicle meningococcal vaccine in preventing hospitalization from gonorrhea in New Zealand: a retrospective cohort study" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "J. Paynter" 1 => "F. Goodyear-Smith" 2 => "J. Morgan" 3 => "P. Saxton" 4 => "S. Black" 5 => "H. Petousis-Harris" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3390/vaccines7010005" "Revista" => array:6 [ "tituloSerie" => "Vaccines (Basel)." "fecha" => "2019" "volumen" => "7" "numero" => "1" "paginaInicial" => "5" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30621260" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bb0035" "etiqueta" => "7." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The serogroup B meningococcal vaccine Bexsero elicits antibodies to <span class="elsevierStyleItalic">Neisseria gonorrhoeae</span>" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "E.A. Semchenko" 1 => "A. Tan" 2 => "R. Borrow" 3 => "K.L. Seib" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/cid/ciy1061" "Revista" => array:7 [ "tituloSerie" => "Clin Infect Dis." "fecha" => "2019" "volumen" => "69" "numero" => "7" "paginaInicial" => "1101" "paginaFinal" => "1111" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30551148" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bb0040" "etiqueta" => "8." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Analysis of the genetic differences between <span class="elsevierStyleItalic">Neisseria meningitidis</span> and <span class="elsevierStyleItalic">Neisseria gonorrhoeae</span>: two closely related bacteria expressing two different pathogenicities" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "C.R. Tinsley" 1 => "X. Nassif" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1073/pnas.93.20.11109" "Revista" => array:7 [ "tituloSerie" => "Proc Natl Acad Sci U S A." "fecha" => "1996" "volumen" => "93" "numero" => "20" "paginaInicial" => "11109" "paginaFinal" => "11114" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8855317" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bb0045" "etiqueta" => "9." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Genetic similarity of gonococcal homologs to meningococcal outer membrane proteins of serogroup B vaccine" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:7 [ 0 => "H. Marjuki" 1 => "N. Topaz" 2 => "S.J. Joseph" 3 => "K.M. Gernert" 4 => "E.N. Kersh" 5 => "Antimicrobial-Resistant Neisseria gonorrhoeae Working Group" 6 => "X. Wang" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1128/mBio.01668-19" "Revista" => array:4 [ "tituloSerie" => "mBio" "fecha" => "2019" "volumen" => "10" "numero" => "5" ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bb0050" "etiqueta" => "10." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "OpcA and PorB are novel bactericidal antigens of the 4CMenB vaccine in mice and humans" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "V. Viviani" 1 => "A. Fantoni" 2 => "S. Tomei" 3 => "S. Marchi" 4 => "E. Luzzi" 5 => "M. Bodini" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/s41541-023-00651-9" "Revista" => array:5 [ "tituloSerie" => "npj Vaccines." "fecha" => "2023" "volumen" => "8" "paginaInicial" => "54" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/37045859" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bb0055" "etiqueta" => "11." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Bacteremia and rheumatic symptoms in patients from lyme disease-endemic region" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "C. Ben Beard" 1 => "C.A. Nelson" 2 => "P.S. Mead" 3 => "L.R. Petersen" 4 => "Bartonella spp." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3201/eid1811.120675" "Revista" => array:7 [ "tituloSerie" => "Emerg Infect Dis." "fecha" => "2012" "volumen" => "18" "numero" => "11" "paginaInicial" => "1918" "paginaFinal" => "1919" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23092626" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bb0060" "etiqueta" => "12." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Computational identification, characterization and validation of potential antigenic peptide vaccines from hrHPVs E6 proteins using immunoinformatics and computational systems biology approaches" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Khan" 1 => "M. Junaid" 2 => "A.C. Kaushik" 3 => "A. Ali" 4 => "S.S. Ali" 5 => "A. Mehmood" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1371/journal.pone.0196484" "Revista" => array:4 [ "tituloSerie" => "PLoS One" "fecha" => "2018" "volumen" => "1:13" "numero" => "5" ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bb0065" "etiqueta" => "13." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The use of liposomes to shape epitope structure and modulate immunogenic responses of peptide vaccines against HIV MPER" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "B. Apellániz" 1 => "J.L. Nieva" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/bs.apcsb.2015.03.002" "Revista" => array:6 [ "tituloSerie" => "Adv Protein Chem Struct Biol." "fecha" => "2015" "volumen" => "99" "paginaInicial" => "15" "paginaFinal" => "54" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26067815" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bb0070" "etiqueta" => "14." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A synthetic M protein peptide synergizes with a CXC chemokine protease to induce vaccine-mediated protection against virulent streptococcal pyoderma and bacteremia" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "M. Pandey" 1 => "E. Langshaw" 2 => "J. Hartas" 3 => "A. Lam" 4 => "M.R. Batzloff" 5 => "M.F. Good" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.4049/jimmunol.1500157" "Revista" => array:6 [ "tituloSerie" => "J Immunol." "fecha" => "2015" "volumen" => "15:194" "numero" => "12" "paginaInicial" => "5915" "paginaFinal" => "5925" ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bb0075" "etiqueta" => "15." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Immunoinformatics and structural vaccinology driven prediction of multi-epitope vaccine against Mayaro virus and validation through in-silico expression" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Khan" 1 => "A. Khan" 2 => "A.U. Rehman" 3 => "I. Ahmad" 4 => "S. Ullah" 5 => "A.A. Khan" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.meegid.2019.06.006" "Revista" => array:6 [ "tituloSerie" => "Infect Genet Evol." "fecha" => "2019" "volumen" => "73" "paginaInicial" => "390" "paginaFinal" => "400" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31173935" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bb0080" "etiqueta" => "16." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Quantification by LC-MS(E) of outer membrane vesicle proteins of the Bexsero® vaccine" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:10 [ 0 => "C. Tani" 1 => "M. Stella" 2 => "D. Donnarumma" 3 => "M. Biagini" 4 => "P. Parente" 5 => "A. Vadi" 6 => "C. Magagnoli" 7 => "P. Costantino" 8 => "F. Rigat" 9 => "N. Norais" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.vaccine.2014.01.011" "Revista" => array:7 [ "tituloSerie" => "Vaccine" "fecha" => "2014" "volumen" => "32" "numero" => "11" "paginaInicial" => "1273" "paginaFinal" => "1279" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24462403" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bb0085" "etiqueta" => "17." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "<span class="elsevierStyleItalic">Neisseria gonorrhoeae</span> lipooligosaccharide glycan epitopes recognized by bactericidal IgG antibodies elicited by the meningococcal group B-directed vaccine, MenB-4C" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "Y.-L. Tzeng" 1 => "S. Sannigrahi" 2 => "R. Borrow" 3 => "D.S. Stephens" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3389/fimmu.2024.1350344" "Revista" => array:3 [ "tituloSerie" => "Front. Immunol." "fecha" => "2024" "volumen" => "15" ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bb0090" "etiqueta" => "18." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Recent progress towards a gonococcal vaccine" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "S.A. Maurakis" 1 => "C.N. Cornelissen" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3389/fcimb.2022.881392" "Revista" => array:4 [ "tituloSerie" => "Front Cell Infect Microbiol." "fecha" => "2022" "volumen" => "11" "numero" => "12" ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bb0095" "etiqueta" => "19." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Vaccine value profile for <span class="elsevierStyleItalic">Neisseria gonorrhoeae</span>" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "Y. Lyu" 1 => "A. Choong" 2 => "E.P.F. Chow" 3 => "K.L. Seib" 4 => "H.S. Marshall" 5 => "M. Unemo" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.vaccine.2023.01.053" "Revista" => array:3 [ "tituloSerie" => "Vaccine" "fecha" => "2023" "volumen" => "13" ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bb0100" "etiqueta" => "20." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A gonococcal vaccine has the potential to rapidly reduce the incidence of <span class="elsevierStyleItalic">Neisseria gonorrhoeae</span> infection among urban men who have sex with men" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "B.B. Hui" 1 => "T.N. Padeniya" 2 => "N. Rebuli" 3 => "R.T. Gray" 4 => "J.G. Wood" 5 => "B. Donovan" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/infdis/jiab581" "Revista" => array:6 [ "tituloSerie" => "J Infect Dis." "fecha" => "2022" "volumen" => "15;225" "numero" => "6" "paginaInicial" => "983" "paginaFinal" => "993" ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bb0105" "etiqueta" => "21." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Vaccines against gonorrhea: current status and future challenges" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "A.E. Jerse" 1 => "M.C. Bash" 2 => "M.W. Russell" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.vaccine.2013.08.067" "Revista" => array:6 [ "tituloSerie" => "Vaccine" "fecha" => "2014" "volumen" => "32" "numero" => "14" "paginaInicial" => "1579" "paginaFinal" => "1587" ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bb0110" "etiqueta" => "22." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Exploitation of <span class="elsevierStyleItalic">Neisseria meningitidis</span> group B OMV vaccines against <span class="elsevierStyleItalic">N. gonorrhoeae</span> to inform the development and deployment of effective gonorrhea vaccines" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "H. Petousis-Harris" 1 => "F.J. Radcliff" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3389/fimmu.2019.00683" "Revista" => array:5 [ "tituloSerie" => "Front Immunol." "fecha" => "2019" "volumen" => "10" "paginaInicial" => "683" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31024540" "web" => "Medline" ] ] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bb0115" "etiqueta" => "23." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Experimental gonococcal urethritis and reinfection with homologous gonococci in male volunteers" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K.A. Schmidt" 1 => "H. Schneider" 2 => "J.A. Lindstrom" 3 => "J.W. Boslego" 4 => "R.A. Warren" 5 => "L. Van de Verg" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/00007435-200110000-00001" "Revista" => array:7 [ "tituloSerie" => "Sex Transm Dis." "fecha" => "2001" "volumen" => "28" "numero" => "10" "paginaInicial" => "555" "paginaFinal" => "564" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11689753" "web" => "Medline" ] ] ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bb0120" "etiqueta" => "24." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Weaponized health communication: Twitter bots and Russian trolls amplify the vaccine debate" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D.A. Broniatowski" 1 => "A.M. Jamison" 2 => "S. Qi" 3 => "L. AlKulaib" 4 => "T. Chen" 5 => "A. Benton" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2105/AJPH.2018.304567" "Revista" => array:7 [ "tituloSerie" => "Am J Public Health." "fecha" => "2018" "volumen" => "108" "numero" => "10" "paginaInicial" => "1378" "paginaFinal" => "1384" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30138075" "web" => "Medline" ] ] ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bb0125" "etiqueta" => "25." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cellular immune responses in humans induced by two serogroup B meningococcal outer membrane vesicle vaccines given separately and in combination" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "F. Oftung" 1 => "G.E. Korsvold" 2 => "A. Aase" 3 => "L.M. Næss" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1128/CVI.00666-15" "Revista" => array:7 [ "tituloSerie" => "Clin Vaccine Immunol." "fecha" => "2016" "volumen" => "23" "numero" => "4" "paginaInicial" => "353" "paginaFinal" => "362" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26865595" "web" => "Medline" ] ] ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bb0130" "etiqueta" => "26." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Implementation of immuno-chemoinformatics approaches to construct multi-epitope for vaccine development against omicron and delta SARS-CoV-2 variants" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "A. Dawood" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.vacun.2022.05.006" "Revista" => array:6 [ "tituloSerie" => "Vacunas" "fecha" => "2022" "volumen" => "23" "numero" => "S2" "paginaInicial" => "18" "paginaFinal" => "31" ] ] ] ] ] ] ] ] ] ] "agradecimientos" => array:1 [ 0 => array:4 [ "identificador" => "xack762380" "titulo" => "Acknowledgments" "texto" => "<p id="p0195" class="elsevierStylePara elsevierViewall">The author thanks college of Medicine, University of Mosul for documenting this work.</p>" "vista" => "all" ] ] ] "idiomaDefecto" => "en" "url" => "/15769887/unassign/S1576988724000736/v1_202407290418/en/main.assets" "Apartado" => null "PDF" => "https://static.elsevier.es/multimedia/15769887/unassign/S1576988724000736/v1_202407290418/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1576988724000736?idApp=UINPBA00004N" ]
Journal Information
Special Articles
Available online 29 July 2024
Designing an immuno-epitope candidate vaccine from (Opa, ProA, ProB, RmpM and BamD) proteins against Neisseria gonorrhoeae and Neisseria meningitides
Diseño de una vacuna candidata a inmunoepítopo a partir de proteínas (Opa, ProA, ProB, RmpM y BamD) contra Neisseria gonorrhoeae y Neisseria meningitidis
Ali Adel Dawood
Corresponding author
Dept. of Medical Biology, College of Medicine, University of Mosul, Mosul, Iraq